Press release archive
Browse GSK's global press release archive for media and investors. Search by keyword or browse by year/business category.
Press releases issued by our local operating companies can be viewed on our market websites.
GlaxoSmithKline and Human Genome Sciences announce FDA approval of Benlysta® (belimumab) for the treatment of systemic lupus erythematosus
GSK & HGS announced that the FDA has approved Benlysta for the treatment of active, autoantibody-positive SLE who are receiving therapy.
GlaxoSmithKline plc appoints two Non-Executive Directors to its Board (1)
GSK announces, Ms. Judy Lewent and Ms. Stacey Cartwright have been appointed as Non-Executive Directors and will join the Board from 1/4/11.
GSK outlines new plan to drive recruitment and attract graduate talent in the UK
GSK outlined new plans to encourage talented students graduating from UK universities to consider pursuing a career within the company.
Regulatory update: Nimenrix® (MenACWY vaccine)
GSK submitted a MAA to EMA for Nimenrix, active immunisation against meningococcal diseases caused by Neisseria meningitidis serogroups.
World’s first everyday fluoride toothpaste with NovaMin® technology that can repair sensitive teeth
GlaxoSmithKline Consumer Healthcare today announced a breakthrough in dental care with the launch of new Sensodyne Repair & Protect.
Reward for charities bridging gaps in health care provision
Ten UK charities have each won £25,000 in recognition of their outstanding contribution to improving health care, part of GSK IMPACT Awards.
David Redfern appointed as new Chairman of ViiV Healthcare
GSK, ViiV & Pfizer announced the appointment of David Redfern as the new Chairman of the Board for ViiV Healthcare with effect from 1/4/11.
GSK European regulatory update on Pandemrix™ (1)
CHMP concludes that data are insufficient to establish a causal relationship between Pandemrix and narcolepsy.
First African country introduces GSK’s pneumococcal vaccine through innovative financing mechanism
GSK announced the incorporation of its pneumococcal vaccine into the Kenyan national immunisation programme.
GlaxoSmithKline moving to new building at Philadelphia Navy Yard
GSK & LRY announced they signed a 15.5-year lease for a new building to be developed by Liberty Property Trust and Synterra Partners.
GlaxoSmithKline and Human Genome Sciences announce publication of BLISS-52 phase lll study results for Benlysta® in The Lancet
GSK & HGS announced publication Benlysta in autoantibody-positive patients with active systemic lupus erythematosus (SLE) in The Lancet.
GSK revises US Avandia label to include new restrictions on use
GSK announced revised US prescribing information and medication guides for all rosiglitazone-containing medicines.
GSK and Theravance announce progression of LAMA/LABA combination treatment into Phase III development for COPD
GSK & THRX announced major milestones in two clinical development programmes focused on new treatments for patients with COPD.
GSK results announcement for the fourth quarter
Strategic progress drives positive underlying sales growth, increasing pipeline potential and improved cash generation.
Update on Pandemrix™ and interim Finnish report on narcolepsy
GSK is aware of today's interim report by the Finnish National narcolepsy committee on their investigation into reported cases in Finland.
GSK announces the sale of its entire shareholding in Quest Diagnostics
GSK announces that it has sold its entire holding of 30,755,151 shares of common stock in Quest Diagnostics Inc. (Quest).
GSK and Actelion discontinue clinical development of almorexant
GSK & ATLN announced the Phase III investigational dual orexin receptor antagonist, almorexant, has been discontinued.
GSK receives FDA Complete Response letter for Avodart for prostate cancer risk reduction supplemental indication
GSK received a Complete Response letter from the FDA for the sNDA for Avodart for reducing the risk of prostate cancer in men.
GlaxoSmithKline announces start of two phase III studies in advanced/metastatic melanoma
GSK announced the start of two global Phase III studies in advanced or metastatic melanoma patients with a BRAF V600 mutation.
Regulatory update - GSK and Valeant receive positive opinion in Europe from the CHMP for Trobalt (retigabine)
GSK & VRX announced EMA's CHMP has issued a positive opinion, recommending marketing authorisation for Trobalt, treatment of seizures.